Duspatalin, 135 mg 50 pcs.

Myotropic antispasmodic, has a direct effect on the smooth muscles of the gastrointestinal tract (mainly large intestine). It eliminates spasm without affecting normal intestinal peristalsis. It has no anticholinergic effect.

Pharmacokinetics

In oral administration, it undergoes presystemic hydrolysis and is not detected in plasma. It is metabolized in the liver to veratric acid and mebeverine alcohol. It is excreted mainly by kidneys as metabolites, in small amounts – with bile.

The mebeverine capsules have properties of prolonged release. Even after repeated administration, there is no significant cumulation.

Indications

Symptomatic treatment of pain, spasms, dysfunction and intestinal discomfort associated with irritable bowel syndrome. Symptoms may include: abdominal pain, cramping, feeling of bloating and flatulence, change in stool frequency (diarrhea, constipation, or alternating diarrhea and constipation), change in stool consistency.

Pharmacological effect

Antispasmodic myotropic action, has a direct effect on the smooth muscles of the gastrointestinal tract (mainly the large intestine). Eliminates spasm without affecting normal intestinal motility. Does not have anticholinergic effects.

Pharmacokinetics

When taken orally, it undergoes presystemic hydrolysis and is not detected in plasma. Metabolized in the liver to veratric acid and mebeverine alcohol. It is excreted mainly by the kidneys in the form of metabolites, in small quantities with bile.

Mebeverine capsules have sustained release properties. Even after repeated administration, no significant accumulation is observed.

Special instructions

Before taking Duspatalin®, you should consult your doctor if:
if symptoms of the disease appeared for the first time;
unintentional and unexplained weight loss;
anemia;
rectal bleeding or blood in the stool;
fever;
if anyone in your family has been diagnosed with colon cancer, celiac disease or inflammatory bowel disease;
over 50 years of age and if symptoms of the disease appeared for the first time;
recent use of antibiotics.
Contact your doctor if your condition worsens while taking the drug or if your symptoms do not improve after 2 weeks of use.

Active ingredient

Mebeverine

Composition

1 tab. contains:

Active substances:

mebeverine hydrochloride 135 mg,

Excipients:

lactose monohydrate – 97 mg,

potato starch – 45 mg,

povidone K25 – 5.5 mg,

talc – 12 mg,

magnesium stearate – 5.5 mg.

Shell composition: talc – 40 mg, sucrose – 79 mg, gelatin – 0.4 mg, acacia gum – 0.4 mg, carnauba wax – 0.3 mg.

Pregnancy

It is not recommended to use Duspatalin® during pregnancy.

Duspatalin® should not be taken while breastfeeding.

Contraindications

hypersensitivity to any component of the drug.
age up to 18 years.
congenital intolerance to galactose (lactose) or fructose, lactase deficiency, sucrase/isomaltase deficiency, glucose-galactose malabsorption syndrome.
pregnancy and breastfeeding period.

Side Effects

For the skin: urticaria (allergic rash), angioedema (serious allergic reaction, which may include: difficulty breathing, swelling of the face, neck, lips, tongue, throat), facial swelling, exanthema (skin rash).

On the part of the immune system: hypersensitivity reactions (anaphylactic reactions – serious allergic reactions, which may include: difficulty breathing, rapid pulse, a sharp decrease in blood pressure (weakness and dizziness), sweating).

Interaction

Animal studies have demonstrated the absence of any interaction between Duspatalin® and ethyl alcohol.

Overdose

In case of overdose with Duspatalin®, you should immediately consult a doctor.

Symptomatic treatment is recommended.

Storage conditions

At a temperature not exceeding 30°C (5-30°C), out of the reach of children.

Shelf life

2 years

Manufacturer

Veropharm LLC, Russia